NCT02711423View on ClinicalTrials.gov

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 28, 2016

Study Completion Date

September 28, 2016

Conditions

Healthy Volunteer

Interventions

DRUG

Gantenerumab

Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.

DRUG

Placebo

Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.

Trial Locations (1)

32806

Bioclinica Research, Orlando

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02711423 - A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter